November 4, 2026
Reporter: Joseph Wilson
LONDON, United Kingdom — England is preparing to launch a major medical research programme that could change how some of the world's most difficult-to-detect cancers are identified, with more than 20,000 National Health Service (NHS) patients expected to participate in a world-first clinical trial involving advanced blood tests.
The initiative will examine whether relatively simple blood tests can help family doctors identify signs of multiple cancers earlier, potentially allowing patients to receive further investigations and treatment before their diseases reach advanced stages.
The trial, announced on November 4 by the British government, will operate through at least 200 general practitioner (GP) practices across England. It will focus particularly on cancers affecting the abdomen, including bowel, pancreatic, stomach, liver and ovarian cancers, as well as prostate and several other cancers.
Patients aged 45 and older who visit participating GP practices with symptoms such as persistent bloating, abdominal discomfort or other unexplained problems may be invited to take part.
The programme is being led by researchers at the University of Birmingham and supported by the UK government's Office for Life Sciences and the National Institute for Health and Care Research (NIHR).
The government has committed up to £8.49 million to fund the research.
How the New Cancer Blood Tests Will Work
The proposed technology is designed to identify biological signs associated with cancer by analysing a patient's blood.
Unlike conventional diagnostic approaches that investigate one suspected cancer at a time, the tests being evaluated in the trial are designed to look for signals associated with several cancers using a single blood sample.
Researchers will examine different biological indicators, including proteins and other markers that may suggest the presence of cancer.
Some of the technologies will use artificial intelligence (AI) to help analyse the results and identify patterns that could otherwise be difficult to recognise.
Most participants will need only one or two tubes of blood collected at their GP practice, alongside routine blood tests.
The tests are also designed to provide an indication of where in the body a possible cancer may be developing. This information could help doctors determine which patients require further examinations and specialist referrals.
However, the technology is not intended to replace established diagnostic procedures. A positive blood test will not automatically mean that someone has cancer.
Instead, it will provide additional information to help GPs decide whether a patient should undergo further investigation.
Which Cancers Will the Trial Investigate?
The STRIDE-RCT trial will examine blood tests designed to detect signs associated with 13 cancer types.
These include:
| Cancer type | Why earlier detection matters |
|---|---|
| Bowel cancer | Early diagnosis can improve treatment options and survival. |
| Small bowel cancer | Symptoms may be vague and difficult to identify. |
| Stomach cancer | Early symptoms can resemble common digestive problems. |
| Oesophageal cancer | Diagnosis may be delayed when symptoms are initially unclear. |
| Pancreatic cancer | Often difficult to detect before advanced disease develops. |
| Liver cancer | Early symptoms may be limited or nonspecific. |
| Bile duct cancer | Can be difficult to recognise in its early stages. |
| Gallbladder cancer | May be discovered during investigations for other conditions. |
| Ovarian cancer | Symptoms such as bloating can be mistaken for less serious conditions. |
| Endometrial cancer | Early investigation of warning symptoms is important. |
| Kidney cancer | Some patients experience few noticeable symptoms initially. |
| Bladder cancer | Early recognition of symptoms can support timely investigation. |
| Prostate cancer | Blood-based indicators may help identify patients needing further assessment. |
The research is particularly important because several of these cancers are frequently diagnosed after they have already progressed.
Researchers want to determine whether testing for multiple cancer signals at the primary-care level can help doctors recognise potential disease sooner.
Why England Is Focusing on Early Cancer Detection
Cancer remains one of the leading causes of death in the United Kingdom and other developed countries.
One of the major challenges facing healthcare professionals is that many cancers initially produce symptoms that are difficult to distinguish from ordinary illnesses.
For example, persistent bloating, abdominal pain, indigestion, changes in bowel habits and unexplained discomfort can result from several different medical conditions.
A patient experiencing these symptoms may not necessarily have cancer. However, in some cases, the symptoms may be early indications of a serious disease.
The difficulty for GPs is determining which patients need urgent specialist investigations and which can safely receive routine treatment or monitoring.
The British government says approximately 71,000 people in England are diagnosed annually with pancreatic, stomach, liver, ovarian or bowel cancer. Nearly 35,000 deaths are associated with these cancers each year.
The new trial is intended to investigate whether blood testing can improve the identification of patients who need further examination.
The Difference Between Early-Stage and Advanced Cancer
The potential importance of early diagnosis can be illustrated by survival statistics for bowel cancer.
According to the British government's announcement, approximately nine out of every 10 people diagnosed with stage 1 bowel cancer survive for at least five years.
By comparison, only around one out of every 10 people diagnosed at stage 4 survives for at least five years.
This difference demonstrates why researchers are interested in technologies that could help identify cancers before they spread.
| Bowel cancer stage | Approximate proportion surviving at least five years |
|---|---|
| Stage 1 | 90% |
| Stage 4 | 10% |
These figures are population-level statistics, not predictions of an individual patient's outcome. Survival also depends on factors such as age, overall health, cancer characteristics and available treatment.
Nevertheless, the difference highlights the importance of detecting cancer before it reaches an advanced stage.
More Than 200 GP Practices Will Participate
The trial will involve at least 200 GP practices across England.
Researchers intend to include practices serving different communities, including inner-city populations, rural areas, coastal towns and communities experiencing economic deprivation.
This approach is important because access to healthcare, patterns of disease and the likelihood of receiving an early diagnosis can vary considerably between communities.
By involving different types of communities, researchers hope to establish whether the tests can work effectively across the wider NHS population rather than only in a limited group of patients.
People aged 45 and older who visit participating practices with abdominal symptoms, including persistent bloating or discomfort, may be offered the opportunity to participate.
The research team will assess the blood-test results alongside doctors' clinical assessments to determine whether the technology improves decision-making.
Why the Trial Is Called a World First
The significance of the STRIDE-RCT programme is not simply that researchers are developing another cancer blood test.
Several companies and research institutions have already developed technologies intended to identify multiple cancers through blood samples.
What makes this study particularly important is its investigation of how different blood-test technologies can be used directly in routine primary-care settings, where patients initially present their symptoms to family doctors.
The researchers want to establish whether these tests can help GPs identify which patients need urgent investigations and whether they can improve the overall diagnostic process.
The trial will evaluate the technologies alongside doctors' existing clinical judgement.
This distinction is important because a test that can detect biological signals in a laboratory does not automatically prove that it improves patient outcomes when used in everyday healthcare.
The study is therefore designed to generate evidence before the NHS considers whether the approach should be introduced more widely.
Could the Tests Reduce Pressure on Hospitals?
Another important objective is to improve how healthcare resources are used.
Currently, only around 2% to 6% of patients referred urgently for suspected cancer in England are ultimately diagnosed with cancer, according to the government's announcement.
This means many people undergo urgent investigations even though they do not have the disease.
Although these referrals are necessary to avoid missing serious illnesses, they can place considerable pressure on hospitals, specialist clinics and diagnostic services.
The new blood tests could potentially help doctors identify which patients require urgent referrals and which may need alternative investigations or monitoring.
If the technology proves reliable, it could help reduce unnecessary investigations while allowing patients with concerning results to receive attention sooner.
However, researchers must establish that the tests are sufficiently accurate and safe before recommending their widespread use.
What Happens When a Blood Test Indicates Possible Cancer?
A positive result will not automatically confirm that a patient has cancer.
Instead, the result will provide information that the GP can consider alongside the patient's symptoms, medical history, examination findings and other test results.
Depending on the circumstances, the doctor may recommend additional investigations, which could include imaging, specialist consultations or a biopsy.
A biopsy involves collecting a small sample of tissue for laboratory examination. In many cases, this is necessary to establish whether cancer is actually present and identify its type.
This means that even if the new technology identifies a potential cancer signal, patients may still need conventional diagnostic procedures before receiving a confirmed diagnosis.
Researchers will also need to examine how frequently the tests produce false-positive results, where a test suggests possible cancer but subsequent investigations do not confirm the disease.
They must also determine whether the tests miss cancers that are actually present.
These questions will be central to deciding whether the technology should become part of routine NHS care.
Government Commits Millions to Cancer Research
The British government has committed up to £8.49 million through the Office for Life Sciences and the National Institute for Health and Care Research to support the programme.
The funding forms part of wider government efforts to improve cancer diagnosis, strengthen medical research and encourage the development of new healthcare technologies.
Health Secretary Yvette Cooper said earlier diagnosis gives patients a better chance of successful treatment and that the research would establish whether simple blood tests could help GPs identify patients requiring urgent support sooner.
The government has also linked the programme to its broader National Cancer Plan, which aims to improve diagnosis, treatment and patient care.
The University of Birmingham is leading the research, with clinical investigators working to determine whether the technology can deliver meaningful improvements in real-world healthcare.
Experts Say the Technology Must Be Properly Tested
Although the announcement has generated considerable interest, medical researchers have emphasized that the blood tests must undergo rigorous evaluation.
Professor Aneel Bhangu, a consultant colorectal surgeon and one of the trial's co-chief investigators, said doctors frequently encounter patients who have experienced vague symptoms for months before receiving a cancer diagnosis.
He also highlighted the challenge of referring patients urgently when most ultimately do not have cancer.
The trial is intended to determine whether blood tests can help distinguish patients who require further investigation from those whose symptoms are caused by less serious conditions.
Cancer Research UK has also welcomed the research, describing the difficulty of identifying cancer when symptoms overlap with common illnesses as an important challenge in primary care.
The organization has emphasized that the findings will be valuable in determining whether the technology can help doctors identify patients who need further tests.
The researchers are therefore not presenting the blood tests as a confirmed replacement for existing cancer screening programmes. Their purpose is to establish whether the technology provides a reliable additional tool for doctors.
What This Could Mean for the Future of Cancer Diagnosis
If the trial produces positive results, the technology could eventually change how some cancers are investigated in primary care.
Instead of relying entirely on symptoms and individual cancer-specific tests, doctors may have access to a blood test capable of identifying signals associated with several different cancers at once.
Such an approach could be particularly useful for diseases that are difficult to recognise during their early stages.
It could also encourage further investment in artificial intelligence, laboratory technology and personalised diagnostic medicine.
However, the future of multi-cancer blood testing will depend on more than the ability to identify biological markers.
Researchers must demonstrate that the tests are accurate, that positive results lead to appropriate follow-up investigations and that their use improves outcomes for patients.
They must also consider affordability, access, privacy and the potential anxiety associated with false-positive results.
The STRIDE-RCT trial is an important step toward answering those questions.
Important Warning: The Blood Test Is Not Yet a General Cancer Screening Service
Despite the excitement surrounding the announcement, members of the public should understand that the programme is a clinical trial, not a nationwide service available to everyone.
Participation will be through selected GP practices, with eligible patients aged 45 and older who present with relevant symptoms potentially invited to take part.
The tests are being evaluated to determine whether they should eventually be introduced more widely.
People should not assume that a routine blood test can currently rule out every cancer or that a negative result means further medical assessment is unnecessary.
Anyone experiencing persistent, unexplained or concerning symptoms should contact a healthcare professional, even if previous blood tests have been normal.
Early medical assessment remains important because no single test can currently detect every type of cancer with complete accuracy.
Conclusion: A Promising Step Toward Earlier Cancer Detection
England's decision to launch a large-scale clinical trial involving more than 20,000 patients represents an important development in cancer research.
By investigating whether advanced blood tests can identify signals associated with 13 different cancers, researchers hope to give family doctors another tool for recognising patients who may need urgent investigations.
The programme could help address one of the most difficult challenges in modern healthcare: identifying serious diseases when their earliest symptoms are often vague and easily mistaken for less serious conditions.
For patients, the potential benefit is significant. Earlier diagnosis may create more opportunities for treatment before cancer spreads, while better identification of high-risk patients could help healthcare systems direct resources where they are most needed.
However, the real value of the technology will depend on the results of the clinical trial.
The next stage is to establish whether these blood tests can deliver reliable results in everyday medical practice and whether they genuinely improve patient outcomes.
If successful, the research could help shape the future of cancer diagnosis not only in England but also in healthcare systems around the world.